Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with HR+/HER2- breast cancer.
No evidence of distant metastatic spread.
Underwent primary breast cancer surgery (mastectomy/lumpectomy) during the study period.
Initiated adjuvant ET within 12 months of surgery date and after September 17, 2024, to the period up to 3 months prior to the data cutoff date.
Had at least one visit during the baseline period and at least one visit one day after the index date.
Patients included must have met one of the following conditions at the time of diagnosis or surgery:
1. Nodal stage (N) N2 or N3 disease.
2. N1 any anatomic tumor size (T), including micrometastatic patients except T0 N1mi and T1 N1mi; For T0 N1mi and T1 N1mi patients with Grade 3 disease alone will be selected.
3. Node-negative with the following high-risk criteria:
1. Tumor size is T3, T4
2. Tumor size is T2 and Grade 3
3. Tumor size is T2 with Grade 2 and either Ki-67 score ≥ 20% or genomic high risk based on Oncotype Dx/Mammaprint/Endopredict/Prosigna
You may not be if
Use of any prior CDK4/6i before the index date.
Missing T or N values for both clinical and surgical stage.
Diagnosis of cancer other than breast cancer.
Evidence of participation in a clinical trial at any time during the study observation period.
Clareo Health | A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors
